Clinical Trial

Phase ll Study of HEC585 in Patients With IPF

Name: Phase ll Study of HEC585 in Patients With IPF — clinical trial record (NCT05060822)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2021-09-18; most recent amendment 2026-04-16.

Status change: Recruiting → Active, Not Recruiting 2026-04-16

Trial Details

NCT Number	NCT05060822
Lead Sponsor	Sunshine Lake Pharma Co., Ltd.
Conditions	Idiopathic Pulmonary Fibrosis
Enrollment	270 participants
Start Date	2021-06-30
Primary Completion	2025-07-16 (estimated)
Study Completion	2026-12-11 (estimated)
Updated on ClinicalTrials.gov	2026-04-21